$GYRE
GYRE THERAPEUTICS, INC.

2016 Q1 Form 10-K Financial Statement

#000119312516498295 Filed on March 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2015 Q3
Revenue $110.0K $110.0K $110.0K
YoY Change 83.33% -13.39% 340.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.400M $3.030M $2.510M
YoY Change 3.45% 180.56% 195.29%
% of Gross Profit
Research & Development $2.286M $1.770M $1.486M
YoY Change 65.29% 26.43% 11.23%
% of Gross Profit
Depreciation & Amortization $105.0K $100.0K $100.0K
YoY Change -7.08% -75.0% -50.0%
% of Gross Profit
Operating Expenses $4.681M $4.794M $3.994M
YoY Change 26.38% 94.09% 82.79%
Operating Profit -$4.572M -$4.683M -$3.885M
YoY Change 50.79% 160.46% 137.18%
Interest Expense $980.0K -$450.0K $1.439M
YoY Change 476.47% -190.0% 28680.0%
% of Operating Profit
Other Income/Expense, Net $20.00K -$467.0K
YoY Change -78.26% -435.97%
Pretax Income -$3.590M -$5.130M -$5.050M
YoY Change -46.66% 294.62% 4.15%
Income Tax
% Of Pretax Income
Net Earnings -$3.592M -$5.129M -$5.051M
YoY Change 25.68% 293.93% 236.28%
Net Earnings / Revenue -3265.45% -4662.73% -4591.82%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.724M -$6.662M -$14.03M
COMMON SHARES
Basic Shares Outstanding 11.43M shares 11.43M shares 34.29M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.70M $32.50M $36.80M
YoY Change -73.57% 2066.67% -62.41%
Cash & Equivalents $20.58M $29.10M $23.10M
Short-Term Investments $7.100M $3.400M $13.70M
Other Short-Term Assets $32.70M $35.70M $35.40M
YoY Change 8075.0% 8825.0% 3440.0%
Inventory
Prepaid Expenses
Receivables $400.0K $500.0K $600.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $60.74M $68.70M $72.85M
YoY Change -42.29% 3218.74% -26.4%
LONG-TERM ASSETS
Property, Plant & Equipment $682.0K $698.0K $709.0K
YoY Change 82.84% -23.38% 46.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $800.0K
YoY Change -95.18%
Other Assets $100.0K $100.0K $100.0K
YoY Change 1011.11% 733.33% 426.32%
Total Long-Term Assets $807.0K $823.0K $1.659M
YoY Change -57.53% -9.66% -90.32%
TOTAL ASSETS
Total Short-Term Assets $60.74M $68.70M $72.85M
Total Long-Term Assets $807.0K $823.0K $1.659M
Total Assets $61.54M $69.52M $74.51M
YoY Change -42.56% 2232.14% -35.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $717.0K $939.0K $669.0K
YoY Change -39.7% 277.11% 83.79%
Accrued Expenses $1.000M $1.500M $1.300M
YoY Change -63.15% -40.22% -45.15%
Deferred Revenue
YoY Change
Short-Term Debt $30.90M $33.70M $34.80M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.33M $37.76M $37.91M
YoY Change 753.98% 1516.27% 1080.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $200.0K $300.0K $400.0K
YoY Change -72.73%
Total Long-Term Liabilities $200.0K $300.0K $400.0K
YoY Change -72.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.33M $37.76M $37.91M
Total Long-Term Liabilities $200.0K $300.0K $400.0K
Total Liabilities $33.55M $38.10M $38.31M
YoY Change 759.7% 1002.31% 1092.62%
SHAREHOLDERS EQUITY
Retained Earnings -$134.6M -$131.0M -$125.9M
YoY Change -57.93% 12.7% -59.2%
Common Stock $11.00K $1.000K $11.00K
YoY Change -67.65% -97.06% -67.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.99M $31.43M $36.21M
YoY Change
Total Liabilities & Shareholders Equity $61.54M $69.52M $74.51M
YoY Change -42.56% 2232.14% -35.83%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$3.592M -$5.129M -$5.051M
YoY Change 25.68% 293.93% 236.28%
Depreciation, Depletion And Amortization $105.0K $100.0K $100.0K
YoY Change -7.08% -75.0% -50.0%
Cash From Operating Activities -$4.700M -$5.100M -$9.700M
YoY Change 56.67% -120.4% 27.63%
INVESTING ACTIVITIES
Capital Expenditures $89.00K -$100.0K -$200.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$3.700M $11.00M $26.70M
YoY Change -1950.0% -156.41% 161.76%
Cash From Investing Activities -$3.800M $11.00M $26.50M
YoY Change -2000.0% -156.41% 159.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 200.0K 3.900M
YoY Change -100.0% -89.47% -2050.0%
NET CHANGE
Cash From Operating Activities -4.700M -5.100M -9.700M
Cash From Investing Activities -3.800M 11.00M 26.50M
Cash From Financing Activities 0.000 200.0K 3.900M
Net Change In Cash -8.500M 6.100M 20.70M
YoY Change -1800.0% -17.57% 762.5%
FREE CASH FLOW
Cash From Operating Activities -$4.700M -$5.100M -$9.700M
Capital Expenditures $89.00K -$100.0K -$200.0K
Free Cash Flow -$4.789M -$5.000M -$9.500M
YoY Change 59.63% -120.0% 25.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
318000
CY2015Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
183000
CY2015Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
73692000
CY2015Q3 cbio Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accounts Payable And Accrued Expenses
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses
4963000
CY2015Q3 cbio Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash Cash Equivalents And Marketable Securities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashCashEquivalentsAndMarketableSecurities
41154000
CY2015Q3 cbio Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
37000000
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11430104 shares
CY2015Q2 dei Entity Public Float
EntityPublicFloat
63198734
CY2009Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
100000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6290
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
193177 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.12
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-93340000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3401000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
245849 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.88
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2517000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-103008000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2828000
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
87405011 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
250255 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370944 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
87405011 shares
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.96
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370944 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
88469871 shares
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2336000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6923000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6649000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
281000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
729000
CY2014Q4 us-gaap Liabilities
Liabilities
3456000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
26000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2570000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1750000
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
391000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51975000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116275000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-109352000
CY2014Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
391000
CY2014Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
118678000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2981000
CY2014Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
108877000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
391000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
249000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1546000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
911000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
2070000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2014Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
278000
CY2014Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
95000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1544000
CY2014Q4 us-gaap Assets
Assets
2981000
CY2014Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1546000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44083000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
103000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7560000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1382000
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1546000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6467000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 cbio Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
43000
CY2015Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2199509 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
9.99
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
103129 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.99
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
105000000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2139323 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11430085 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1560477 shares
CY2015Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.84
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11430085 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
180954 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37756000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162450000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5701000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
926000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
292000
CY2015Q4 us-gaap Liabilities
Liabilities
38096000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
19000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1314000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
745000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1156000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
438000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2015Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
33743000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1593000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21655000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
535000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
125000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131037000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
48000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
31425000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1156000
CY2015Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
69521000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
939000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
723000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
66248000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
125000
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
32500000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
698000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
68698000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11060
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
33794000
CY2015Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
133000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
3402000
CY2015Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
492000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29096000
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8080
CY2015Q4 us-gaap Assets
Assets
69521000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
66248000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2015Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
1156000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17650000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1781000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6399000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1285000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
66247000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2625000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 cbio Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
95000
CY2015Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-08-31
CY2015Q2 cbio Extended Lease Expiration Date
ExtendedLeaseExpirationDate
2018-02-27
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3448300 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4641 shares
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6274000
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.45
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.52
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-27.29
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
365214 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M5D
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
57313 shares
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9966000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
298000
CY2013 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
138000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-10120000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
52000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-54000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-9966000
CY2013 us-gaap Contracts Revenue
ContractsRevenue
523000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2013 us-gaap Operating Expenses
OperatingExpenses
10643000
CY2013 us-gaap Depreciation
Depreciation
1000000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5742000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
974000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4086000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2792000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-573000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
298000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
298000
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-247000
CY2013 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
5742000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-41000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6557000
CY2013 cbio License Fees Payable
LicenseFeesPayable
100000
CY2013 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
400000
CY2013 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
154000
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0324 pure
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3627995 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2279 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3425 pure
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.59
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.0197 pure
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6389000
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.82
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.36
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5730 shares
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-17.99
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
367586 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M4D
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0031 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12415 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6613000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
745000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
244000
CY2014 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
156000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-7509000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
53000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-99000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-6613000
CY2014 us-gaap Contracts Revenue
ContractsRevenue
1813000
CY2014 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-354000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-78000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2014 us-gaap Operating Expenses
OperatingExpenses
9322000
CY2014 us-gaap Depreciation
Depreciation
700000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5007000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
680000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4055000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-313000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
98000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-354000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1284000
CY2014 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
53000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
244000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-106000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
244000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2000
CY2014 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
4982000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
28000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
98000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5267000
CY2014 cbio Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Granted
P9Y9M22D
CY2014 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
400000
CY2014 cbio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0183 pure
CY2014 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
896000
CY2014 cbio Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
0.0000 pure
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Trading Symbol
TradingSymbol
CBIO
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001124105
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0133 pure
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6053589 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
36547 shares
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
2.0417 pure
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.98
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.1159 pure
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19118000
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
106787 shares
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.48
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.38
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3820 shares
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.33
CY2015 dei Entity Registrant Name
EntityRegistrantName
CATALYST BIOSCIENCES, INC.
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, convertible notes and related warrants up to the date of conversion, common stock and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p> </div>
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4429093 shares
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
Each share of common stock was entitled to one vote.
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
47.20
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0222 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
675585 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y4M13D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y4M13D
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1511000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
52000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14761000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
272000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
474000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersNet
-774000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
326000
CY2015 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
774000
CY2015 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
242000
CY2015 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-41000
CY2015 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-13802000
CY2015 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000
CY2015 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
5000
CY2015 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
242000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
79000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
91000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
125000
CY2015 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
52000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
117647000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1350000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-14762000
CY2015 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
36537000
CY2015 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
3020000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2015 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
241000
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
82000
CY2015 us-gaap Contracts Revenue
ContractsRevenue
1750000
CY2015 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-91000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000
CY2015 us-gaap Interest Expense
InterestExpense
1478000
CY2015 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
1455000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2015 us-gaap Operating Expenses
OperatingExpenses
15552000
CY2015 us-gaap Depreciation
Depreciation
500000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9313000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
470000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9594000
CY2015 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
100000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1749000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1347000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-91000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
27552000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
326000
CY2015 us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
3255000
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
13823000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4273000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
326000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1150000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
7259000
CY2015 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1888000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
96000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
37357000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5958000
CY2015 cbio Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
1420823 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.60
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3033000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2201000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1724000
CY2015 cbio Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
900000
CY2015 cbio Proceeds From Reverse Merger
ProceedsFromReverseMerger
23931000
CY2015 cbio Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0800 pure
CY2015 cbio Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
518000
CY2015 cbio Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
P4Y6M4D
CY2015 cbio Warrants Exercised Weighted Average Exercise Price
WarrantsExercisedWeightedAverageExercisePrice
9.70
CY2015 cbio Non Cash Interest On Convertible Debt
NonCashInterestOnConvertibleDebt
1478000
CY2015 cbio Sharebased Compensation Arrangements By Sharebased Payment Award Options Assumed In Merger Weighted Average Exercise Price
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
15.16
CY2015 cbio Investment Securities Received From Reverse Merger
InvestmentSecuritiesReceivedFromReverseMerger
17223000
CY2015 cbio Redeemable Convertible Notes Assumed Upon Reverse Merger
RedeemableConvertibleNotesAssumedUponReverseMerger
37073000
CY2015 cbio Derivative Related To Redeemable Convertible Notes
DerivativeRelatedToRedeemableConvertibleNotes
1455000
CY2015 cbio Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
-2.4087 pure
CY2015 cbio Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
5600000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M15D
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.75
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1863000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1734000
CY2014Q1 us-gaap Contracts Revenue
ContractsRevenue
297000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2160000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.67
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2858000
CY2015Q1 us-gaap Contracts Revenue
ContractsRevenue
672000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
3704000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.68
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2210000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2075000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
297000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2507000
CY2015Q2 us-gaap Contracts Revenue
ContractsRevenue
860000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3060000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.08
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1638000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-1502000
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
547000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
2185000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3885000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-5051000
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
109000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
3994000
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.51
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1798000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-1302000
CY2014Q4 us-gaap Contracts Revenue
ContractsRevenue
672000
CY2014Q4 us-gaap Operating Expenses
OperatingExpenses
2470000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4683000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-5129000
CY2015Q4 us-gaap Contracts Revenue
ContractsRevenue
109000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
4794000

Files In Submission

Name View Source Status
0001193125-16-498295-index-headers.html Edgar Link pending
0001193125-16-498295-index.html Edgar Link pending
0001193125-16-498295.txt Edgar Link pending
0001193125-16-498295-xbrl.zip Edgar Link pending
cbio-20151231.xml Edgar Link completed
cbio-20151231.xsd Edgar Link pending
cbio-20151231_cal.xml Edgar Link unprocessable
cbio-20151231_def.xml Edgar Link unprocessable
cbio-20151231_lab.xml Edgar Link unprocessable
cbio-20151231_pre.xml Edgar Link unprocessable
d117011d10k.htm Edgar Link pending
d117011dex211.htm Edgar Link pending
d117011dex231.htm Edgar Link pending
d117011dex311.htm Edgar Link pending
d117011dex312.htm Edgar Link pending
d117011dex321.htm Edgar Link pending
d117011dex322.htm Edgar Link pending
d117011dex43.htm Edgar Link pending
d117011dex44.htm Edgar Link pending
d117011dex45.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g117011dsp009.jpg Edgar Link pending
g117011g03g10.jpg Edgar Link pending
g117011g06t23.jpg Edgar Link pending
g117011g13s55.jpg Edgar Link pending
g117011g99b35.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending